Previous reports have indicated that the upregulated TGF-β originated from cancer cells, since immunohistochemical and/or in situ hybridisation studies demonstrated that the TGF-βs were localised in tumour cytoplasm (Friess et al, 1993; Coppola et al, 1998). The gene discussed is TGFB1; the disease is cancer.